Clinical bottom line
Eosinophilic esophagitis (EoE) management continues to evolve with advances in pharmacologic and dietary therapies. Topical corticosteroids, particularly budesonide, remain first-line treatments, while biologics such as dupilumab show promise for refractory cases. Nutritional management through elimination diets is effective but requires careful patient selection and monitoring. Endoscopic interventions play a supportive role in managing strictures. Emerging evidence from systematic reviews and clinical studies supports a personalized, multidisciplinary approach to optimize symptom control and histologic remission (Chowdhury et al., 2026; Samanta et al., 2026; Pasta et al., 2025).
What the evidence shows
Chowdhury et al. (2026) conducted a systematic review and meta-analysis comparing budesonide and dupilumab in EoE treatment. Budesonide demonstrated significant efficacy in inducing histologic remission and symptom improvement, with a favorable safety profile. Dupilumab, a monoclonal antibody targeting IL-4/IL-13 pathways, showed promising results in patients with moderate-to-severe or steroid-refractory EoE, though long-term data remain limited.
Samanta et al. (2026) provide a comprehensive overview of evolving therapeutic strategies in pediatric EoE, emphasizing the role of dietary elimination (such as the six-food elimination diet) alongside pharmacotherapy. They highlight the importance of balancing efficacy with quality of life, noting that diet adherence can be challenging.
Pasta et al. (2025) review endoscopic management, underscoring that dilation is effective for fibrostenotic complications but should be adjunctive to medical therapy to control underlying inflammation.
Abonia and colleagues (2024) discuss therapeutic management, noting that while topical steroids and dietary interventions remain cornerstones, emerging biologics and small molecules targeting eosinophilic inflammation pathways are expanding the therapeutic arsenal.
Reed et al. (2019) provide foundational insights into EoE pathophysiology and treatment, supporting current approaches and highlighting the need for ongoing research into novel agents.
Caveats and uncertainty
Most biologic therapies are relatively new with limited long-term safety and efficacy data in diverse populations.
Dietary elimination requires patient motivation and multidisciplinary support; nutritional deficiencies and adherence issues may limit effectiveness.
Endoscopic dilation carries risks such as perforation and should be reserved for selected cases.
Heterogeneity in study designs and outcome measures complicates direct comparisons of therapies.
Individual response variability necessitates personalized treatment plans.
How this may change practice
Clinicians should consider integrating biologic agents like dupilumab for patients with refractory or severe EoE, particularly when corticosteroids and diet fail.
Dietary management remains a key component, especially in pediatric populations, with emphasis on patient education and nutritional monitoring.
Endoscopic dilation should be employed judiciously for strictures, in conjunction with anti-inflammatory therapy.
Multidisciplinary teams including gastroenterologists, allergists, dietitians, and pathologists can optimize individualized care.
Ongoing surveillance and adaptation of treatment plans based on response and tolerance will improve long-term outcomes.